Please login to the form below

Not currently logged in
Email:
Password:

Abexinostat

This page shows the latest Abexinostat news and features for those working in and with pharma, biotech and healthcare.

Servier announces job cuts as pressures mount

Servier announces job cuts as pressures mount

Servier has also had some pipeline setbacks of late. Last year the company abandoned development of its HDAC inhibitor abexinostat for cancer, returning rights to Pharmacyclics, while in October it walked

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    And finally, Xynomic, the US/China biopharmaceutical company has picked up two products: ACAT-1 from the US company Resarci Therapeutics and abexinostat from a mystery seller who Xynomic declined to ... name. (Abexinostat was formerly in development by

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics